Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2019

THE CARDIOVASCULAR MARKET IN ROMANIA DURING 1998 – 2017 PERIOD – ANALYSIS AND EVOLUTION

MARIAN PANĂ 1#, PETRU CRĂCIUN 1#, CAMELIA NICOLAE 2#, ADRIANA-ELENA TĂEREL 3*, DUMITRU LUPULIASA 1

1.Pharmaceutical Technology and Biopharmacy Department, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 .Cardiology Department, Panduri Hospital, Bucharest, Romania
3 .Department of Pharmaceutical Management and Marketing, Faculty of Pharmacy, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

Download Full Article PDF

By all dimensions of analysis: units, DOT and values, the cardiovascular market has grown significantly over the last twenty years. However, it is still questionable if this development is enough, as cardiovascular diseases account for the most important mortality factor in Romania. Concerning therapeutic groups, of used cardiovascular drugs the biggest share in days of treatment belongs to C9 (inhibitors of the renin-angiotensin system), followed at certain distance by C10 (anti-atheroma agents and lipid regulators), C1 (cardiac therapy), C7 (beta-blocking agents), C8 (calcium antagonists) and C3 (diuretics). Regarding channels, retail channel accounts for dispensing almost all cardiovascular drugs. By administration route, oral solid forms are by far the most used form. Taking into consideration the product type, generic medicines are dominating in volume, while original medicines leads in value. Concerning market layers, volume and value of cardiovascular drugs are balanced between the 3 layers, while almost 2/3 of the population stays in the 3rd layer, which raises questions about the treatment accessibility in small cities and villages. Regarding INNs, there is a significant dynamic over the time; currently the most used are metoprolol, indapamide and atorvastatin.